Copyright
©The Author(s) 2024.
World J Clin Cases. May 6, 2024; 12(13): 2194-2200
Published online May 6, 2024. doi: 10.12998/wjcc.v12.i13.2194
Published online May 6, 2024. doi: 10.12998/wjcc.v12.i13.2194
Variable | Treatment group (n = 40) | Control group (n = 40) | P value |
Age (yr) | 58.3 ± 9.2 | 57.6 ± 8.7 | 0.68 |
Sex (male/female) | 28/12 | 26/14 | 0.67 |
Tumor stage (I/II/III) | 10/18/12 | 12/16/12 | 0.81 |
Surgical approach (open/thoracoscopic) | 22/18 | 24/16 | 0.69 |
RDQ score | 25.4 ± 9.8 | 24.8 ± 10.2 | 0.76 |
Variable | Treatment group (n = 40) | Control group (n = 40) | P value |
LESP (mmHg) | Baseline: 11.2 ± 3.4 | Baseline: 10.8 ± 3.6 | < 0.01 |
End: 15.6 ± 4.2a | End: 12.4 ± 3.8a | ||
PA (mmHg) | Baseline: 38.6 ± 11.2 End: 52.4 ± 12.6a | Baseline: 37.4 ± 10.8 End: 41.2 ± 11.4a | < 0.01 |
PV (cm/s) | Baseline: 2.8 ± 0.9 End: 3.6 ± 1.1a | Baseline: 2.7 ± 0.8 End: 2.9 ± 0.9a | < 0.01 |
- Citation: Zhang YJ, Wu SP. Therapeutic effect of Wendan Decoction combined with mosapride on gastroesophageal reflux disease after esophageal cancer surgery. World J Clin Cases 2024; 12(13): 2194-2200
- URL: https://www.wjgnet.com/2307-8960/full/v12/i13/2194.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i13.2194